Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 24;7(10):386.
doi: 10.3390/microorganisms7100386.

Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270"

Despoina Koulenti  1   2 , Elena Xu  3 , Isaac Yin Sum Mok  4 , Andrew Song  5 , Drosos E Karageorgopoulos  6 , Apostolos Armaganidis  7 , Jeffrey Lipman  8   9   10 , Sotirios Tsiodras  11
Affiliations

Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270"

Despoina Koulenti et al. Microorganisms. .

Abstract

On 18 August 2019, an article was published in Microorganisms presenting novel, approved anti-Gram-positive antibiotics. On 19 August 2019, the U.S. Food and Drug Administration announced the approval of lefamulin, a representative of a new class of antibiotics, the pleuromutilins, for the treatment of adult community-acquired bacterial pneumonia. We present a brief description of lefamulin.

Keywords: Gram-positive pathogens; lefamulin; multidrug-resistance; novel antibiotics; pleuromutilins.

PubMed Disclaimer

Conflict of interest statement

Author J.L. reports: Advisory Board with Bayer and MSD and honorarium for lectures from Pfizer and MSD. All other authors (D.K., E.X., A.S., I.Y.S.M., D.E.K., A.A., and S.T.) declare no competing interests.

Comment on

  • Microorganisms. 7:270.

References

    1. Koulenti D., Xu E., Mok I.Y.S., Song A., Karageorgopoulos D.E., Armaganidis A., Lipman J., Tsiodras S. Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms. 2019;7:270. doi: 10.3390/microorganisms7080270. - DOI - PMC - PubMed
    1. Label (PDF)-FDA. XENLETA (Lefamulin). HIGHLIGHTS OF PRESCRIBING INFORMATION. [(accessed on 16 September 2019)]; Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211....
    1. Eyal Z., Matzov D., Krupkin M., Wekselman I., Paukner S., Zimmerman E., Rozenberg H., Bashan A., Yonath A. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci. Rep. 2016;6:39004. doi: 10.1038/srep39004. - DOI - PMC - PubMed
    1. Eyal Z., Matzov D., Krupkin M., Wekselman I., Paukner S., Zimmerman E., Rozenberg H., Bashan A., Yonath A. Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus. Proc. Natl. Acad. Sci. USA. 2015;112:E5805–E5814. doi: 10.1073/pnas.1517952112. - DOI - PMC - PubMed
    1. Paukner S., Sader H.S., Streit J.M., Flamm R.K., Gelone S.P. In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015) Open Forum Infect. Dis. 2017;4(Suppl. 1):S373. doi: 10.1093/ofid/ofx163.916. - DOI

LinkOut - more resources